Before it's too late: Why synthetic biologists need an open-parts collaboration - And how to build one

EMBO Reports

Volumn 10, Issue 8, 2009, Pages 806-809

  Maurer, Stephen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN;

ALTRUISM; ARTICLE; COMPUTER PROGRAM; DNA SEQUENCE; GENE SEQUENCE; LICENCE; PATENT; PRIORITY JOURNAL; PUBLISHING; SCIENTIFIC LITERATURE; SEQUENCE HOMOLOGY;

BIOLOGY; COOPERATIVE BEHAVIOR;

EID: 68249083972     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2009.165     Document Type: Article

References (8)

1. Cohn D (2005) Open-source biology evolves. Wired, January 17
2. DiMasi J, Paquett C (2004) The economics of follow-on drug research and development. Pharmacoeconomics 22 (Suppl 2): 1-14
3. Henkel J (2006) Selective revealing in open innovation processes: The case of embedded LINUX. Res Policy 35: 953-969
4. Henkel J, Maurer S (2007) The economics of synthetic biology. Mol Syst Biol 3:117
5. Jefferson R (2006) Science as social enterprise: The Cambia Bios initiative. Innovation 4: 13-44
6. Lawrence S (2008) Biotech patents: Business as usual? Nat Biotechnol 26: 1326
7. Maurer S, Scotchmer S (2006) Open-source software: The new intellectual property paradigm. In Handbook on Information Systems, T Hendershott (Ed), pp 285-322. Amsterdam, the Netherlands: Elsevier
8. US Supreme Court (1947) Transwrap Machine Corporation vs. Stokes & Smith Co. 329 U.S. 637